BIAL

About BIAL

BIAL is a 100-year-old innovation-driven biopharmaceutical company dedicated to

discovering, developing, and commercializing medicines.

Being a fully integrated company strongly committed to therapeutic innovation,

BIAL has established an ambitious R&D program, consistently investing more than

20% of its annual revenue in this field. Key focus areas for the company are the

neurosciences and rare diseases.

As a result of a longstanding strategy focused on R&D, BIAL has launched and

commercialised two medicines: eslicarbazepine acetate in 2009 and opicapone in

2016.

The launch of its research drugs was crucial to boosting BIAL’s internationalisation.

In Europe, BIAL has a production site and R&D unit in Portugal (headquarters) and

affiliates in several countries - Spain, Germany, United Kingdom, Italy, and

Switzerland. Additionally, BIAL is also present in the US and emerging markets such

as Mozambique, Angola, Ivory Coast, and Panama.

The company’s internationalisation strategy also sought the establishment of

partnerships and license agreements with well-established partners namely in the

US, Japan, China, Australia, and South Korea. BIAL products are present in fifty

countries, fulfilling its purpose of making a real difference in the lives of people

living with severe diseases across the world.